Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633895 | 0.93 | USP2 (0.35) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL23123018 | 0.87 | — | — | |
| SCHEMBL3687892 | 0.85 | USP2 (0.30) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7401284 | 0.82 | USP2 (0.45) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL10065580 | 0.80 | USP2 (0.39) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL29140307 | 0.78 | — | — | |
| SCHEMBL13377909 | 0.77 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL14858101 | 0.76 | PDE7B (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL4048080 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL671851 | 0.76 | USP2 (0.56) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-29 | — | — | US | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2023-06-01 | — | — | US | disclosed |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-03-07 | — | — | US | disclosed |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | MINDSET PHARMA INC. (CA) | 2023-02-28 | — | — | US | disclosed |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| US-20220017550-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | MINDSET PHARMA INC. (CA) | 2022-01-20 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20200123142-A1 | Substituted Cyclohexylamine Compounds | Epizyme, Inc. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-8143443-B2 | Process for preparing gabapentin | ZACH SYSTEM S.P.A. (IT) | 2012-03-27 | — | — | US | disclosed |
| US-20120046272-A1 | Novel Therapeutic Compounds | GRUNENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046272-A1 | Novel Therapeutic Compounds | GRUNENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | ZACH SYSTEM S.P.A. (IT) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123142-A1 | Substituted Cyclohexylamine Compounds | SMYD3, SMYD2, SNRPD3 | USP2 783/4885ALDH1A1 1867/4885LMNA 4325/4885 |
| US-20220017550-A1 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR3A, TPH1, HTR5A | USP2 4703/4885ALDH1A1 2224/4885LMNA 2030/4885 |
| US-20100029983-A1 | PROCESS FOR PREPARING GABAPENTIN | GABRB1, GABRG1, OGDH | USP2 2740/4885ALDH1A1 55/4885LMNA 1746/4885 |
| US-20220024956-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | USP2 4487/4885ALDH1A1 2787/4885LMNA 255/4885 |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | USP2 424/4885ALDH1A1 1259/4885LMNA 4283/4885 |
| US-20120046272-A1 | Novel Therapeutic Compounds | OPRL1, OPRK1, OPRM1 | USP2 4832/4885ALDH1A1 1493/4885LMNA 3652/4885 |
| US-11597738-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | USP2 4487/4885ALDH1A1 2787/4885LMNA 255/4885 |
| US-20230203070-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | USP2 4487/4885ALDH1A1 2787/4885LMNA 255/4885 |
| US-11591353-B2 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders | HTR1A, HTR6, HTR1B | USP2 4487/4885ALDH1A1 2787/4885LMNA 255/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | USP2 369/4885ALDH1A1 1533/4885LMNA 4437/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | USP2 383/4885ALDH1A1 1575/4885LMNA 4418/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | USP2 525/4885ALDH1A1 2292/4885LMNA 4434/4885 |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | SMYD2, SMYD3, SNRPD2 | USP2 903/4885ALDH1A1 1716/4885LMNA 4320/4885 |
| US-20230167141-A1 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | HTR1A, HTR6, HTR1B | USP2 4487/4885ALDH1A1 2787/4885LMNA 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.